A life sciences venture capital firm based in USA is focused on early and growth-stage biotech and pharma companies. The group has $300M assets under management and recently closed its third fund. Initial investments typically are in the $3M-$8M range and are usually in the form of equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies with products addressing unmet medical needs and unique mechanisms of action. Bios typically invests in companies ranging from late preclinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is looking to make 4-5 investments over the next 6 to 12 months. could lead any investment up to €15M but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider Seed through IPO rounds. The firm focuses on companies based in Europe, but also considers companies in Israel and USA.

The firm will look at a broad spectrum of products and services within the life science space. While the firm has traditionally not considered therapeutics, the firm is now open to making investments in this space. The firm is most interested in medical devices and diagnostics including in-vitro diagnostics, and also looks into digital health. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and have proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA just successfully closed the first round of their fund The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. Regarding specific types of technologies, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm based in Western Europe. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a large strategic platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including large hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Funded in October 2017, the family office focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm has accumulated over 40M CHF investment amount over the past 24 months. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.

The firm looks to invest 70% in Therapeutics, 20% in Medical Devices, and 10% Digital Health/Others. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.

The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

An Innovation Lab that is the open innovation arm of a Japan-headquartered global leader in robotics and automation for manufacturing of electronic devices and the automotive industry. The firm has offices in Cupertino, CA and New York. The firm seeks to identify investment and partnership opportunities that align with its parent company’s business, and is currently focused on early stage (Seed to Series A) companies. The firm has a global outlook and is seeking opportunities in North America, Europe, Asia and beyond.

Within life sciences and healthcare sectors, the firm is interested in the following verticals: support robots, human behavior monitors, and vital sensors. The firm is particularly interested in technologies that address the aging population and those that can significantly improve the quality of life and promote more efficient care management and independence. The firm will openly consider IoT devices and platforms that address this market. The firm is not interested in traditional therapeutics and diagnostics companies.

The firm can act as either lead or co-investor in the companies they invest in. Beyond investment, the firm seeks to collaborate in various ways such as assisting with generating PoC data, assisting further clinical development, navigating and entering the Japanese market, etc. The firm closely communicates with its parent corporation headquarters to support these initiatives.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Founded in 2019, the Venture Capital firm a space technology and human longevity-focused VC based in New York, USA. The firm had its hard launch in December 2020 at TechCrunch Sessions. The firm invests in Pre-seed, Seed, Seed+ companies at $200K with a possible follow-on of $400K and Series A & B rounds at $800K with a potential $1.6M follow-on. The firm will consider opportunities primarily in the Americas, UK, and EU. Also, the firm actively supports companies by providing connections to human capital providers, governmental entities, and suitable investors to help founders grow their business.

The firm will look at a broad spectrum of products and services within space technology and human longevity. The partners had previously invested in 20+ early-stage technology companies/ funds with active private deal-flow in the verticals of space, healthcare, and robotics. The firm is investing in biomarkers, diagnostics, digital health, and therapeutics (RX and OTC), dealing with the hallmarks of aging on the longevity side of things.

The firm will invest in privately held companies only and will participate as a co-investor. The firm prefers to invest in companies with at least three founders and will not invest in sole founder companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.